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doi:10.1016/j.ejvs.2009.11.002Abstract Objective: Lifelong imaging surveillance is currently recommended for all patients
following endovascular aortic aneurysm repair (EVR). The modality, timing and overall neces-
sity of surveillance has recently been brought into question. This review reports contemporary
secondary intervention rates and explores surveillance imaging pick-up rates and reports
the evidence supporting modified EVR surveillance programs.
Design: Systematic review of literature (2002e2009) and meta-analysis of KaplaneMeier
re-intervention-free survival estimates.
Results: 32 Papers were included in final analysis. 17,987 EVR cases were reported. Crude
annual secondary intervention rates from the US population registries were 3.7%/year (range
1.7e4.3%). Combined re-intervention-free survival estimates, from 14 series (10,365 cases),
demonstrated a linear progression with 89.9%, 86.9% and 81.5% of grafts without secondary
procedures at 2, 3 and 5 years respectively.
3 Reports (1249 cases) differentiated between interventions directed by surveillance or
outside surveillance protocols. Surveillance imaging alone initiated the secondary interven-
tions in 1.4e9% of cases; >90% of EVR cases received no benefits from surveillance scans.
Discussion: Some format of surveillance following EVR probably remains necessary despite
a reduction in secondary interventions with modern stent-grafts. Surveillance should be tar-
geted at those stent-grafts and patients at high risk of complications. Further work is justified
to identify this group.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.87255315; fax: þ44 2087253495.
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Endovascular abdominal aortic aneurysm repair (EVR) is
becoming more widely applied to elective abdominal aortic
aneurysm (AAA) repair due to its lower aneurysm-related
operative and mid-term mortality rates.1 However this
technique incurs additional costs.2 These costs are amplified
when graft surveillance and secondary intervention expenses
are added to the equation. Intensive radiological surveillance
is not routine following open surgery.
Graft surveillance following EVR is currently universally
recommended, although there are no standard regimes.
The rationale for surveillance is prevention of AAA rupture
or AAA/stent-graft associated morbidity and mortality.
Intensive surveillance regimens may be the consequence
of early, first generation graft failures.3 Evidence is required
to assure the licensing bodies and profession of the durability
of modern stent-grafts. The indications for secondary inter-
ventions have changed over time with the recognition of
factors associated with stent-graft failure, AAA rupture and
other complications.
Computed tomography (CT) scanning was the mainstay of
graft surveillance in early EVR. There are alternative imaging
modalities although none is ideal. Many centres have
proposedaDuplex led surveillanceprogram,although this can
be user-dependent. Magnetic resonance imaging, albeit free
from ionizing radiation, is expensive, has limited availability,
incompatible with some grafts and gadolinium can be neph-
rotoxic. Implantable sensor technology is still in its infancy.
The relative value of lifelong surveillance in patients who
have undergone EVR has become an important topic.
Repeated CT scanning exposes the patient to potential
carcinogenic risks associated with ionizing radiation expo-
sure. The estimated lifetime attributable risk (LAR) of death
from cancer following an abdominal CT scan in a patient>50
years is 0.02%; small, yet cumulative which can become
significant with repeated scanning.4 Repetitive use of iodin-
ated contrast can have a cumulative deleterious effect on
renal function; especially in the elderly and those patients
with pre-existing renal impairment.5
Long-term post-placement surveillance, diagnostic
studies and possible secondary procedures have been shown
to increase the global cost of EVR by nearly 50%.6 Approxi-
mately 65% of follow-up costs have been attributed to CT
scanning.7 Typical post-EVR CT and MR scans cost approxi-
mately £750e1000 and £1000e1300 respectively. In compar-
ison, post-EVR surveillance color-flow duplex ultrasound
(CDU) costs approximately £300e400.8 To develop the role of
EVR cost-effectiveness needs to be improved,6 reducing
unnecessary expenditure on surveillance is one possibility.
This systematic review examines the current rates of
secondary intervention following elective EVR. It explores
whether these interventions were initiated by the surveil-
lance program or patient symptoms. Although patients
whose AAAs go on to rupture despite EVR have a relatively
good outcome;9 the optimum modality of surveillance
should be determined to prevent rupture.
Methods
Medline, Embase and Cochrane library databases were
interrogated. The keyword searches were ‘‘EVAR’’,‘‘Endovascular’’ and ‘‘surveillance’’ and/or ‘‘secondary
intervention’’. Abstracts from all articles that reported
secondary interventions following EVR published 2002e2009
were reviewed. Further potentially useful articles were
identified through scrutiny of references. Articles were
excluded if they reported <100 cases of EVR, reported <1
year median follow-up or were published outside the English
language literature. Retrieved papers were examined for
rates of secondary intervention and endoleak warranting
treatment. The authors explored each report for secondary
interventions directed by surveillance findings or clinical
symptoms.
Statistics
Cumulative survival data were converted to marginal data
reflecting the annual probabilities of re-intervention within
each trial. Missing annual data from individual trials were
interpolated using available biannual data, with the
assumption of a constant re-intervention rate within the
interval. A KaplaneMeier product estimator was then
calculated multiplying the median derived values for (1-
annual probability of re-intervention) to obtain a cumula-
tive KaplaneMeier estimate of re-intervention-free
survival. Confidence intervals for the estimate were
obtained by applying the same calculation to the inter
quartile values of the derived annual probability of re-
intervention.
Results
473 Papers were screened for retrieval. Following review of
abstracts 53/473 (11%) papers were selected for further
assessment. 32 Papers met the inclusion criteria (Fig. 1). A
total 17,987 EVR cases are reported (Table 1). The crude
annual secondary intervention rate in the EVAR trials was
6%/year. Population registries published since the EVAR
trials report lower annual rates of intervention with median
3.7%/year (range 1.7e4.3%/year).
Examining the independent case-series there is a trend of
reducing secondary intervention rates. Studies reporting
in 2003 present a median secondary intervention rate of
6.6%/year (range3.4e48). This compares to 4.5%/year (range
3e12.8) in the 2009 case-series. This may be attributable to
decreased interventions for endoleak as understanding has
developed, specifically type II endoleaks, or improved graft
technology.
Three out of 32 papers (1249 cases) attempted to
differentiate between secondary interventions directed by
surveillance findings, and those as a consequence of patient
symptoms (Table 1). They described between 1.4 and 9% of
patients undergoing interventions as a result of surveillance
findings. Therefore over 90% of all patients receive no
benefit from post-EVR surveillance. Two papers, Black et al.
and Karthikesalingam et al., described the method of
patient presentation for secondary intervention. In the first
series of 417 patients, 4/6 endoleaks presented symptom-
atically between surveillance intervals.10 In the second
series 36/81 (44%) of patients requiring secondary treat-
ments presented with pain either from the aneurysm or
claudication.
Figure 1 QUORUM chart demonstrating literature search outcomes.
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tions were elective and 34% emergent.11 The majority of
their acute interventions were due to acute leg ischaemia
from graft limb kink or occlusion.
Cumulative re-intervention-free survival estimates were
available from 14 trials (Table 2) Only 2 studies provided
data to 7 years;12,13 the remainder were extrapolated to 7
years by assuming a constant re-intervention rate from the
last available annual interval of each study (Fig. 2). This
demonstrates a linear drop-off in re-intervention-free
survival after EVR. Combined re-intervention-free survival
estimates confirm 94%, 89.9%, 86.9%, 84.9% and 81.5% of
grafts do not require secondary procedures at 1, 2, 3, 4 and
5 years, respectively. No specific failure time is identified
that would correlate with graft material failure or native
vessel disease progression within this period of follow-up.
Discussion
The requirement for secondary interventions after EVR
appears to continue throughout the lifetime of the graft,
necessitating a surveillance strategy. Yet it appears only
a small percentage (<10%) of all EVR patients benefit from
post-deployment graft surveillance. This is an important
finding as the additive costs of surveillance are significant in
the overall investment in an EVR program.
The linear drop-off in re-intervention-free survival from
1 to 7 years is perhaps surprising. Neither the raw data nor
the graphic demonstrate the early re-interventions within
the first months following deployment. These are incorpo-
rated into the probabilities at year 1. The early re-inter-
ventions are where intra-operative adjuncts ensuring
aneurysm exclusion are most beneficial.
At 7 years 72% of patients remain free from secondary
interventions. This finding must be interpreted in the
knowledge that at this extent of follow-up a large propor-
tion of patients can become lost to follow-up. The small
proportion of patients with continuing requirements for
secondary interventions would be of interest to study
further. Whether they constitute patients who had chal-
lenging anatomy at their primary operation and underwent
graft deployment outside the industry guidelines, or they
represent patients with pan-aortic disease would help
understand this pattern further.It is apparent that the requirements for secondary inter-
ventions are declining. This transition is multifactorial. Graft
technology is advancing, as is understanding of management
of endoleaks. Post-deployment adjuncts to ensure optimal
aneurysm exclusion at the primary procedure reduce acute
re-interventions. Centralization of endovascular procedures
is focusing expertise and enhancing intra-departmental
standardswhichmay in turn reduce long-term complications.
Identification of the optimal markers of post-EVR aneu-
rysm rupture will direct surveillance. Large aneurysms
(>6.5 cm diameter) have been shown to be associated with
increased rates of aneurysm-related morbidity death post-
EVR.14 A short infra-renal neck and neck angulation >45
are predictors of clinical failure or the need for re-inter-
vention.15 These factors highlight a population where
continued surveillance may be beneficial.
Post-deployment device migration has also been identi-
fiedby theEUROSTARgroupas a poor prognostic sign.16 Stent-
strut failure has been shown to be clinically insignificant.17
The majority of type II endoleaks has been shown to be
benign.18
There is a consistently low surveillance-scan pick-up
rate. This is particularly highlighted in the series from
Charing Cross, London, where only 1.4% of all EVR patients
had a problem detected by surveillance.10 This has led to
investigation into modifications in surveillance regimens.
Current surveillance and proposed modification
Current modalities for EVR surveillance include clinical
assessment, CT scanning, CDU scanning, plain abdominal
radiography, magnetic resonance imaging and angiography
and more recently implantable pressure sensing devices.
Standard surveillance regimens include serial contrast-
enhanced CT scans and plain abdominal radiographs at 1, 6
and 12 months and every 6 months thereafter for the
patients’ lifetime.19
CT angiography (CTA) is established as the current gold-
standard for periodicmonitoring of aneurysm size,migration
and the detection of endoleak. Pertinent negative aspects of
serial CT surveillance exist. Contrast-agent induced neph-
rotoxicity remains a limitation in patients with renal insuf-
ficiency. Cumulative radiation exposure from repeated
studies can present a long-term carcinogenic risk.4
Table 1 Studies retrieved demonstrating secondary interventions.
Series Year of
publication
EVR
cases (n)
Median
follow-up
(years)
Secondary inter
ventions
(% patients)
Re-intervention
for endoleak (%)
Crude annual
re-intervention
rate (%)a
Interventions
picked up by
surveillance
Randomized
studies
EVAR 1 2005 543 4 20 8 5 e
EVAR 2 2005 178 4 26 8 6.5 e
DREAM 2004 171 2 12 e 6 e
Population
registries
Riccoa 2003 1012 1 e 7.5 e
LIFELINE 2005 2664 6 18.3 e 3.1 e
RETA 2005 996 3 11 e 3.6 e
EUROSTAR 2006 2846 2 8.7 4.2 4.3 e
Vogel 2008 1181 5 8.7 e 1.7 e
Sternbergh 2008 714 2.5 9.6 e 3.8 e
Cao 2009 349 2.2 9.5 3.1 4.3 e
Case Control
Criado 2003 240 1.1 3.8 1.3 3.4 e
Matsumura 2003 235 2 13.2 e 6.6 e
Mooreb 2003 573 6 37 e 6.2 e
Elkouri 2003 100 0.6 29 10 48 e
Flora 2003 108 1.6 26 9 16.3 e
Carpenter 2004 192 1.8 12 5 6.6 e
Verhoeven 2004 306 3 15 e 5 e
Biebl 2005 153 1.3 13 e 10 e
Lalka 2005 136 3 12.5 7.3 4.2 e
Oranen 2006 322 3.3 12 e 3.6 e
Hiramoto 2007 325 2.3 8.6 6.7 3.7 e
Abbruzzese 2008 565 2.5 10.6 7.8 4.2 e
Smith 2008 113 2.7 27 9.7 10 e
Traul 2008 245 2.5 6 3 2.4 e
AbuRahma 2009 238 2 25.6þ 12.8 e
Black 2009 417 2.3 7.4 1.9 3 1.4%
Dias 2009 279 4.5 20.4 e 4.5 9%
Espinosa 2009 337 4.9 e 5.6 e e
Jean Baptiste 2009 447 2 6.5 4 3.25 e
Pitoulias 2009 617 3.8 22.5 11.6 5.9 e
Conrad 2009 832 2.9 11 8 3.8 e
Karthikesalingam 2009 553 2.6 12 e 4.6 5.1%
>100 cases, published 2002 or later.
a Only 30% patients completed 1 year surveillance.
b Only 11% patients completed 6 years surveillance.
550 I.M. Nordon et al.Efforts have been made to reduce the frequency of CT
scanning, or replace it with alternative imaging modalities.
It has been proposed that after 1 year CTA can be reserved
for those patients in whom ultrasound identifies growth or
persistently stable aneurysm diameter.20 The value of CTA
at 6 months has also been examined in a prospective study.
Providing the scan at 1-month confirms no endoleaks, the 6
month scan does not identify any clinically significant
findings warranting intervention.21 Equally the early post-
procedural CTA has been questioned. It has been shown
that this scan fails to influence treatment in 99% of cases.22
Color duplex ultrasound (CDU) demonstrates aneurysms
size, arterial flow, endoleaks endograft limb kinking,patency of access vessels and allows the user to examine
sites distant from the endograft (e.g. assessment of wound
complications). It is portable, can be performed at the bed-
side, and does not require ionizing radiation.
When compared to the gold-standard CT imaging, CDU
can miss up to 1/3 of endoleaks detected on CT.23 The
sensitivity for type II endoleaks is its weakness. However,
the significance of a type II endoleak without associated
increase in aneurysm sac size is debatable. Conservative
management of type II endoleaks is not associated with an
increase risk of AAA rupture.24 Current recommendations
target treatment of type II endoleaks for AAA sac enlarge-
ment occurring after 6 months and/or persistence after 12
m
o
-
Table 2 Raw survival data from 14 studies.
Author 0 Year 1 Year 2 Years 3 Years 4 Years 5 Years 6 Years 7 Years
p n p (SE) n p (SE) n p (SE) n p (SE) n p (SE) n p (SE) n p (SE) n
AbuRahma, 2009 L1 1 174 0.958 (0.017) 112 0.936
(0.023)
76 0.922
(0.027)
52
AbuRahma, 2009 L2 1 22 0.944 (0.054) 10 0.826
(0.012)
5 0.826
(0.012)
5
AbuRahma, 2009 L3 1 17 0.929 (0.069) 8 0.929
(0.069)
5 0.929
(0.069)
3
Cao, 2009 1 349 0.94 329 0.92 182 0.87 80 0.739 31
Abbruzese,
2008 Zenith
1 177 0.94 (0.02) 177 0.91
(0.03)
117 0.91
(0.03)
58 0.91
(0.03)
21 0.91
(0.03)
7 0.65
(0.22)
5
Abbruzese,
2008 Gore
1 111 0.98 (0.01) 110 0.91
(0.03)
83 0.86
(0.04)
59 0.86
(0.04)
41 0.82
(0.06)
24 0.76
(0.08)
17
Abbruzese, 2008
Medtronic AneuRx
1 277 0.95 (0.01) 277 0.88
(0.02)
193 0.85
(0.03)
129 0.83
(0.03)
90 0.77
(0.04)
55 0.73
(0.06)
26
EUROSTAR, 2006 1 2846 0.94 2679 0.913 1377 0.88 634 0.86 225
EUROSTAR, 2000 1 1023 0.89 915 325 0.67 102 0.62 24
Jean Baptiste,
2009 AUIS
1 124 0.98 88 0.9 53 0.85 31
Jean Baptiste,
2009 ABIS
1 323 0.96 209 0.92 104 0.92 43
Sampram, 2003 1 703 0.88 (0.015) 0.74
(0.028)
0.65
(0.044)
Coppi, 2008 1 50 0.96 (0.02) 45 0.88
(0.06)
20 0.74
(0.14)
5
Dias, 2009 1 279 0.92 (0.02) 258 0.84
(0.02)
169 0.77
(0.03)
85
ElKouri, 2003 1 100 0.71 25 0.62 9 8
LIFELINE, 2005 1 2664 0.84 (0.007) 2070 0.83
(0.007)
1846 0.82
(0.0077)
1421 0.81
(0.0085)
1092 0.78
(0.01)
630 0.73
Moore, 2003 1 573 0.902
Karthikesalingam,
2009
1 553 0.86 (0.02) 375 0.83
(0.02)
248 0.79
(0.02)
155 0.76
(0.03)
88 0.74
(0.04)
40 0.74
(0.04)
15 0.74
(0.04)
7
nZ number still under observation.
Data presented as probability of re-intervention-free survival (standard error).
E
V
A
R
Su
rve
illa
n
ce
is
N
e
ce
ssa
ry
b
u
t
R
e
q
u
ire
s
R
e
fi
n
e
m
e
n
t
551
Figure 2 Median and inter quartile KaplaneMeier estimates of re-intervention-free survival. Dotted lines: 1st quartile and 3rd
quartile.
552 I.M. Nordon et al.nths.25 Yet, treatment of type II leaks has a high risk of
failure and may not alter overall outcome.24 An ultrasound-
based surveillance program using increasing aneurysm sac
size as a trigger for intervention showed no negative effects
on aneurysm-related survival.20
The majority of secondary procedures for graft related
problems are now performed endovascularly. Catheter-
based re-interventions include balloon angioplasty, stent-
ing, proximal and distal cuff extensions, placement of a new
stent-graft, embolisation of branch vessels and thrombol-
ysis.26 Conversion to open surgery and emergency secondary
interventions are risk factors for morbidity and mortality.27
Intra-operative adjuncts to reduce secondary
interventions
The majority of secondary interventions are performed
within 30 days of deployment.28 Intra-operative adjuncts
that can assess completeness of aneurysm exclusion,
allowing pre-emptive treatment may reduce secondary
interventions and therefore the demands of surveillance.
Prior to performing any completion imaging all stiff wires
and long sheaths should be removed. A kink in the endog-
raft limb that occurs when tortuous iliac arteries are
allowed to return to their natural anatomical position will
only become apparent once these devices are withdrawn.29
A minimum standard of two-view completion angiog-
raphy is required prior to completion surgery. Dynamic CT
(DynaCT) has been shown to be a powerful tool for detec-
tion of endoleaks, limb compression and graft thrombosis
immediately following graft deployment. It is more sensi-
tive than uni-planar angiography and can be performed
prior to the patient transferring from the operating table.30
Timing of surveillance
The goal of EVR is to prevent AAA rupture. Most AAA ruptures
following EVR occur in the first 2e3 years.31 The LIFELINE
registry reported that 85% of secondary interventions were
performed within 30 days of deployment.28 The majority of
secondary interventions for reduced limb blood flow occurs
within 90-days of deployment.10,32 A longitudinal populationstudy, retrospectively analyzing admission codes, reported
the mean time to secondary interventions to be 447 days
(457) for angiography and 357 days (427) for device
specific treatment.33 This correlates with a single-centre
report describing secondary interventions occurring at
a median 16 months post-deployment.34 The efficiency of
follow-up of EVR may be improved if surveillance focuses on
the first 3 years.31
Redefining postoperative surveillance after EVR has led to
recommendations for regimens whose intensity and
frequency are based on early outcomes.35 Recommendations
have evolved based on 5-year follow-up in the US Zenith
trial. In this study patients were followed-upwith plain X-ray
and CTA at 1, 6 and 12 months and yearly thereafter. In
patients without early endoleak the 6 month imaging can be
eliminated. Aortic ultrasound is suggested for long-term
surveillance >1 year.
It is in the best interests of endovascular practitioners to
contribute to the body of evidence regarding secondary
interventions and surveillance. Groups should be encour-
aged to report follow-up and secondary intervention data.
Clear differentiation should be made between interven-
tions directed by surveillance findings and patient symp-
toms. When this data accrues, from reported case-control
studies, the value of surveillance will be quantifiable. This
may eventually demonstrate the need for, as was the case
with infra-inguinal surveillance, a prospective randomized
study of EVR surveillance.High risk grafts for secondary interventions
The risk of endoleak and subsequent secondary interven-
tion increase as the manufacturers’ instructions for use of
endografts are breached. Complicated aortic neck anatomy
including short aortic neck (<15 mm),36,37 excessive neck
angulation (>45)38 and large aortic neck (>28 mm)39 have
all been shown to be risk factors for proximal type 1
endoleak.
Series with large secondary intervention rates report
that the majority of secondary interventions were within 30
days of deployment.28 This highlights another high risk
group, those with an incomplete primary procedure.
Figure 3 Proposed surveillance program.
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Given the evidence presented in this review we propose
a modified surveillance program (Fig. 3). There is strong
evidence that optimal stent-graft positioning and treatment
of endoleaks should be achieved at the primary operation.
DynaCT will ensure confirmation of this. An early pre-
discharge duplex scan will confirm the integrity of the
access vessels and identify any dissection flaps or limb kinks.
All patients should be entered into the surveillance
program. CT scanning is replaced by Duplex scanning. CT
scanning is reserved for cases liable for secondary inter-
ventions identified by type I/III endoleak or increase in
aneurysm sac size. The mean time to secondary interven-
tions is approximately 1e1½ years. We therefore propose
that, if a patient completes 3 years of surveillance without
detection of endoleak or sac enlargement, the patient can
be discharged from follow-up.
Limitations of this study
All studies regarding secondary interventions must be
interpreted with the understanding that graft technology is
evolving. Management of endoleaks is also more advanced
as most stent-graft complications can be managed endo-
vascularly. Early papers report outcomes using endografts
that are now discontinued. Experience in graft deployment
has also been growing during this period. The EUROSTAR
dataset reported outcomes from 93 hospitals with median
experience of 32 cases and relatively short follow-up.40
Now major centres are approaching experience of over 500
cases and greater than 5-year follow-up.
The statistical model used to generate Fig. 2 relies on
interpolation and extrapolation for missing data points. Until
mandatory registries exist for EVR with survival data, this is
the only methodology available to generate global evidence
of re-intervention. The volume of cases it reports enhances
its power, yet even more robust evidence is required.
Conclusion
The requirements for secondary intervention following EVR
appear to be decreasing. This corresponds with a decreased
intervention rate for endoleaks. Advances in graft tech-
nology allied to a growing understanding of endoleak
management may be the explanation for this. If the need
for secondary interventions continues to decline as will the
requirements for intensive surveillance.No perfect surveillance tool exists. It appears that
a select group of EVR patients will continue to require
secondary interventions long after deployment. Individual
follow-up regimens based on peri-procedural risk stratifica-
tion may be the solution for high risk groups. Low risk
patients could be discharged having completed a brief
uncomplicated follow-up.Acknowledgements
The authors would like to thank Dr. Jan Poloniecki for his
statistical advice and assistance during this project.
Conflict of Interest
The authors declare that there are no conflicts of interest.
References
1 Endovascular aneurysm repair versus open repair in patients
with abdominal aortic aneurysm (EVAR trial 1): randomised
controlled trial. Lancet 2005;365(9478):2179e86.
2 Blackhouse G, Hopkins R, Bowen JM, De Rose G, Novick T,
Tarride JE, et al. A cost-effectiveness model comparing endo-
vascular repair to open surgical repair of abdominal aortic
aneurysms in Canada. Value Health 2008;12(2):245e52.
3 Alric P, Hinchliffe RJ, Wenham PW, Whitaker SC, Chuter TA,
Hopkinson BR. Lessons learned from the long-term follow-up of
a first-generation aortic stent graft. J Vasc Surg 2003;37:367e73.
4 Brenner DJ, Hall EJ. Computed tomography e an increasing
source of radiation exposure. N Engl J Med 2007;357:2277e84.
5 Solomon R, DuMouchel W. Contrast media and nephropathy: find-
ings from systematic analysis and food and drug administration
reports of adverse effects. Invest Radiol 2006;41:651e60.
6 Noll Jr RE, Tonnessen BH, Mannava K, Money SR,
Sternbergh 3rd WC. Long-term postplacement costs after endo-
vascular aneurysm repair. J Vasc Surg 2007;46(1):9e15.
7 Prinssen M, Wixon CL, Buskens E, Blankensteijn JD. Surveillance
after endovascular aneurysm repair: diagnostics, complica-
tions, and associated costs. Ann Vasc Surg 2004;18(4):421e7.
8 Sharma P, Kyriakides C. Surveillance of patients post-endovas-
cular aneurysm repair. Postgrad Med J 2007;83:750e3.
9 May J, White GH, Stephen MS, Harris JP. Rupture of abdominal
aortic aneurysm: concurrent comparison of outcome of those
occurring after endovascular repair versus those occurring
without previous treatment in an 11-year single-center experi-
ence. J Vasc Surg 2004;40:860e6.
10 Black SA, Carrell TW, Bell RE, Waltham M, Reidy J, Taylor P.
Long-term surveillance with computed tomography after
554 I.M. Nordon et al.endovascular repair may not be justified. Br J Surg 2009;96(11):
1280e3.
11 Verhoeven EL, Tielliu IFJ, Prins TR, Zeebregts CJAM, van Andringa
de Kempenaer MG, Cina CS, et al. Frequency and outcome of re-
interventions after endovascular repair for abdominal aortic
aneurysm: a prospective cohort study. Eur J Vasc Endovasc Surg
2004;28:357e64.
12 Karthikesalingam A, Holt PJ, Hinchliffe RJ, Nordon IM, Loftus
IM, Thompson MM. Frequency of re-intervention after endo-
vascular aneurysm repair: can post-operative surveillance be
curtailed? Br J Surg, in press.
13 Coppi G, Silingardi R, Saitta G, Gennai S. Single-center experi-
ence with the Talent LPS endograft in patients with at least 5
years of follow-up. J Endovasc Ther 2008;15(1):23e32.
14 Peppelenbosch N, Buth J, Harris PL, Van Marrewijk CJ, Fransen G.
Diameter of abdominal aortic aneurysm and outcome of endo-
vascular aneurysm repair: does size matter? A report from
EUROSTAR. J Vasc Surg 2004;39(2):288e97.
15 Boult M, Babidge W, Maddem G, Barnes M, Fitridge R. Predictors
of success following endovascular aneurysm repair. Eur J Vasc
Endovasc Surg 2006;31:123e9.
16 Van Marrewijk CJ, Fransen G, Laheij RJ, Harris PL, Buth J. Is
a type II endoleak after EVAR a harbinger of risk? Causes and
outcome of open conversion and aneurysm rupture during
follow-up. Eur J Vasc Endovasc Surg 2004;27(2):128e37.
17 Rumball-Smith A, Wright IA, Buckenham TM. Strut failure in the
body of the Zenith abdominal endoprosthesis. Eur J Vasc
Endovasc Surg 2006;32:136e9.
18 Tuerff SN, Rockman CB, Lamparello PJ, Adelman MA,
Jacobowitz GR, Gagne PJ, et al. Are type II (branch vessel)
endoleaks really benign? Ann Vasc Surg 2002;16:50e4.
19 Eksandari MK, Yao JST, Pearce WH, Rutherford RB, Veith FJ,
Harris PL,etal. Surveillanceafter endoluminal repair of abdominal
aortic aneurysms. Cardiovasc Surg 2001;9(5):469e71.
20 Bargellini I, Cioni R, Napoli V, Petruzzi P, Vignali C, Cicorelli A,
et al. Ultrasonographic surveillance with selective CTA after
endovascular repair of abdominal aortic aneurysm. J Endovasc
Ther 2009;16:93e104.
21 Go MR, Barbato JE, Rhee RY, Makaroun MS. What is the clinical
utility of a 6-month computed tomography in the follow-up of
endovascular aneurysm repair patients? J Vasc Surg 2008;47(6):
1181e6 [discussion 1186e7].
22 Waasdorp E, Van Herwaarden JA, van de Mortel RH, Moll FL, de
Vries JP. Early computed tomographic angiography after endovas-
cular repair: worthwhile or worthless? Vascular 2008;16(5):253e7.
23 AbuRahma AF, Welch CA, Mullins BB, Dyer B. Computed tomog-
raphy versus color duplex ultrasound for surveillanceof abdominal
aortic stent-grafts. J Endovasc Ther 2005;12(5):568e73.
24 Rayt HS, Sandford RM, Salem M, Bown MJ, London NJ,
Sayers RD. Conservative management of type 2 endoleaks is not
associated with increased risk of aneurysm rupture. Eur J Vasc
Endovasc Surg 2009;38(6):718e23.
25 Jones JE, Atkins MD, Brewster DC, Chung TK, Kwolek CJ,
Lamuraglia GM, et al. Persistent type 2 endoleak afterendovascular repair of abdominal aortic aneurysm is associated
with adverse late outcomes. J Vasc Surg 2007;46(1):1e8.
26 Brewster DC, Jones JE, Chung TK, Lamuraglia GM, Kwolek CJ,
Watkins MT, et al. Long-term outcomes after endovascular
abdominal aortic aneurysm repair: the first decade. Ann Surg
2006;244(3):426e38.
27 Pitoulias GA, Schulte S, Donas KP, Horsch S. Secondary endo-
vascular and conversion procedures for failed endovascular
abdominal aortic aneurysm repair: can we still be optimistic?
Vascular 2009;17(1):15e22.
28 Lifeline registry of endovascular aneurysm repair: registry data
report. J Vasc Surg 2005;42(1):1e10.
29 Woody JD, Makaroun MS. Endovascular graft limb occlusion.
Semin Vasc Surg 2004;17(4):262e7.
30 Biasi L, Ali T, Ratnam L, Morgan R, Loftus IM, Thompson MM.
DynaCT improves intra-operative quality control during endo-
vascular abdominal aortic aneurysm repair. J Vasc Surg 2009;
49(2):288e95.
31 Schlosser FJV, Gusberg RJ, Dardik A, Lin PH, VerhagenHJ,Moll FL,
et al. Aneurysm rupture after EVAR: can the ultimate failure be
predicted. Eur J Vasc Endovasc Surg 2009;37(1):15e22.
32 Moore WS, Matsumura JS, Makaroun MS, Katzen BT, Deaton DH,
Decker M, et al. Five-year interim comparison of the Guidant
bifurcated endograft with open repair of abdominal aortic
aneurysm. J Vasc Surg 2003;38(1):46e55.
33 Vogel TR, Symons RG, Flum DR. Longitudinal outcomes after
endovascular repair of abdominal aortic aneurysms. Vasc
Endovascular Surg 2008;42(5):412e9.
34 Dias NV, Riva L, Ivancev K, Resch T, Sonesson B, Malina M. Is
there a benefit of frequent CT follow-up after EVAR? Eur J Vasc
Endovasc Surg 2009;37(4):425e30.
35 Sternbergh 3rd WC, Greenberg RK, Chuter TA, Tonnessen BH.
Redefining postoperative surveillance after endovascular
aneurysm repair: recommendations based on 5-year follow-up
in the US Zenith multicenter trial. J Vasc Surg 2008;48(2):278e
84 [discussion 284e5].
36 Leurs LJ, Kievit J, Dagnelie PC, Nelemans PJ, Buth J. Influence
of infrarenal neck length on outcome of endovascular abdom-
inal aortic aneurysm repair. J Endovasc Ther 2006;13:640e8.
37 Aburahma AF, Campbell J, Stone PA, Nanjundappa A, Jain A,
Dean LS, et al. The correlation of aortic neck length to early
and late outcomes in endovascular aneurysm repair patients.
J Vasc Surg; 2009.
38 Sternbergh 3rd WC, Carter G, York JW, Yoselevitz M, Money SR.
Aorticneckangulationpredictsadverseoutcomewithendovascular
abdominal aortic aneurysm repair. J Vasc Surg 2002;35(3):482e6.
39 Stanley BM, Semmens JB, Mai Q, Goodman MA, Hartley DE,
Wilkinson C, et al. Evaluation of patient selection guidelines
for endoluminal AAA repair with the Zenith stent-graft: the
Australasian experience. J Endovasc Ther 2001;8(5):457e64.
40 Laheij RJ, van Marrewijk CJ, Buth J, Harris PL. The influence of
team experience on outcomes of endovascular stenting of
abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2002;
24(2):128e33.
